Tailoring Strategies to APAC’s Diverse Clinical Trial Environment

The Asia-Pacific region (APAC) is increasingly being seen as a strategic destination for clinical research, but it comes with unique operational challenges for global sponsors. Differences in regulatory frameworks, timelines, site capabilities, and patient demographics mean that success requires far more than simply expanding the geographic scope of a study. In many cases, sponsors rely on specialized clinical research organizations (CROs)—such as Indero, which focuses on supporting clinical trials in complex therapeutic areas—to help navigate these regional differences and manage execution across diverse health care systems. This article explores the most common hurdles, from navigating variable approval pathways to tailoring recruitment strategies and respecting cultural expectations, and outlines practical lessons to help sponsors run high-quality, timeline-driven trials across APAC’s complex clinical landscape.

Why APAC matters

The APAC region has a population of more than 4.5 billion people and is highly diverse, ranging from large middle-income countries and high-tech economies to some of the world’s most populous nations and the small island states of Oceania. APAC is not a single market, and success is highly dependent on a thorough understanding of country-specific regulatory, operational, and cultural differences. However, the opportunities are large, particularly as increasing pressure on sponsors forces acceleration of timelines and a need to broaden recruitment for clinical trials beyond North America and Europe. Many global sponsors are now designing trials with APAC included at the outset, a shift in strategy, as the region was previously used only when Western recruitment slowed.

Expanding a clinical trial into APAC is not simply a matter of transferring and executing a protocol designed for the US or Europe. The region has a number of diverse approaches to regulatory requirements, varying operational environments, and differing industrial cultures, making a “copy-paste’’ expansion strategy ineffective. Successful clinical trial expansion into APAC depends on carefully aligning country selection with the specific objectives of the trial. Within the region, there is a collection of distinct regulatory and operational ecosystems, each offering different advantages depending on the stage and requirements of a development program. For example, Australia and New Zealand have streamlined pathways for approval and offer strong support for early-stage trials, including first-in-human (FIH) trials. Because both countries have the added benefit of English-speaking populations, documents prepared for other English-speaking markets typically do not require translation. South Korea and Japan both have strong clinical trial infrastructure, and Japan is also strategically important for studies involving aging populations while maintaining rigorous safety standards. Meanwhile, China and India offer large patient pools and lower costs, making them attractive for high-volume phase 2 and 3 trials. Despite the diversity of approaches, regulators are also taking steps toward greater harmonization and efficiency, with agencies such as China’s National Medical Products Administration and Japan’s Pharmaceuticals and Medical Devices Agency introducing updates to improve review and approval timelines, including changes announced in early 2026. In parallel, there is increasing alignment with digital and decentralized trial models, following the direction set by the International Council for Harmonisation Good Clinical Practice guidelines E6(R3).

Alongside these established strengths, the region is undergoing a broader transformation in its clinical trials landscape. Across APAC, the rapid adoption of precision medicine and advanced therapeutic modalities is reshaping trial design and strengthening site capabilities, with markets investing heavily in infrastructure and expertise. All these factors position the region as an important location for future clinical development.

Regulatory pathways: speed where you plan for it

Regulatory approvals in the region are often perceived as complex or unpredictable. In practice, timelines are frequently efficient and reliable when sponsors understand each country’s approval model and prepare submissions accordingly. The lack of an overarching body responsible for regulatory oversight means sponsors can strategically leverage the different regulatory structures across countries. In some nations, most notably Australia, the primary review authority sits with ethics committees, although the role of the national regulator is becoming increasingly prominent in the oversight and audit of clinical trials. This structure allows rapid study initiation, particularly when submissions are complete and well prepared. In contrast, other countries operate with more formal regulatory review frameworks, in which authorities expect highly detailed documentation, often in the local language, before granting approval. An example of this is South Korea, which applies a document-intensive process, with the regulator requiring submission of extensive data packages. These more stringent regulatory requirements do not necessarily create longer timelines, but they do mean that packages need to be thorough and carefully assembled.

Global regulatory precedents can also play an important role in facilitating approvals across the region. If a study protocol or product has already received authorization or review from an agency such as the US Food and Drug Administration and the European Medicines Agency, this information can be submitted as a supporting document to regulators in APAC markets, providing reassurance around study design and safety data and helping to streamline the review process.

Recruitment realities across APAC

APAC is associated with strong patient recruitment potential. Large populations, such as those of India and China, naturally create opportunities for recruitment at scale, even for trials involving diseases with relatively low prevalence. Population size alone is not the major determinant, as even smaller nations, such as South Korea, consistently demonstrate strong recruitment performance due to a highly developed clinical research infrastructure with significant experience in running trials. Alongside infrastructure, investigator engagement is another important factor. In some countries, particularly China, South Korea, and Japan, many clinicians are deeply engaged in scientific research and highly motivated to contribute to clinical studies and the resulting publications. The research-intensive environment can create highly committed local partnerships.

The prevalence of a specific disease within a country or health care system also matters significantly more than the overall population size, particularly in a diverse region like APAC, where disease prevalence varies significantly due to local factors. An important principle in site selection is that choosing a small number of highly experienced centers with the right patient populations often produces stronger recruitment outcomes than activating a large number of sites lacking expertise or patient access. With careful site selection, sponsors may be surprised how quickly recruitment in the APAC region outpaces that of Western nations.

Culture, relationships, and expectations on the ground

Cultural expectations shape how clinical trials are initiated and managed across APAC, sometimes in ways that differ significantly from what sponsors may be used to in Europe and North America. In many countries, early in-person engagement with investigators and site teams remains essential for building trust and confirming site commitment, well before formal study activation. In markets such as Japan, China, and Taiwan, sites expect clinical research associates to visit early in the process to discuss details of the planned study. This emphasis on relationship-building may be unfamiliar to Western sponsors, who are used to conducting feasibility studies remotely.

In this context, CROs working within the region often play an important role as a cultural translator between sponsors and investigators. Teams with local expertise can help to improve understanding of cultural expectations, explain the importance of different approaches to study initiation, and facilitate communication between international sponsors and local teams. Respecting local working practices enables smoother study start-up and can influence recruitment momentum and patient retention.

Early- and late-phase strategies in APAC

APAC’s traditional strength has been hosting later-phase trials. Countries such as China, Japan, and India offer access to large patient populations and well-developed hospital networks, with investigators who are experienced in supporting large multicenter studies. These factors make the region particularly valuable for phase 2 and 3 trials, where large-scale recruitment and robust data generation are critical.

Beyond large patient populations for late-stage trials, APAC is increasingly becoming an important location for FIH and early-phase studies. Australia is a world leader in such studies due to efficient regulatory processes and well-established research units. Under the Clinical Trial Notification system, many studies can progress quickly once ethics approval is obtained, allowing trials to be initiated in a short timeframe. These factors have made Australia the nation of choice for many sponsors, both within APAC and from further afield, leading to a buildup of substantial expertise among local medical professionals. Sponsors often choose to run FIH trials in Australia, generating initial safety and pharmacokinetic data before continuing development in their home markets.

The complementary strengths of different nations within APAC mean that studies across the entire development lifecycle are being run in the region, rather than relying on it only for patient recruitment when trials struggle elsewhere. Sponsors who integrate the region early in their development planning can benefit from both the speed of early-phase environments and the recruitment strength of later-phase trial networks.

What are the operational considerations sponsors often overlook?

There are several operational considerations that sponsors must consider alongside regulatory and recruitment planning when conducting trials across APAC. These details are manageable and are not barriers in and of themselves but can have a significant impact on timelines if not anticipated early in the planning process.

One example is the handling and transport of biological samples. In some countries, including China and Malaysia, exporting human samples for analysis outside the country requires specific permits and regulatory approvals to ensure appropriate oversight. Securing permission adds steps to the regulatory process, and sponsors unaware of these details may encounter avoidable delays. Import and export restrictions can also affect the movement of investigational products and clinical supplies, with many nations requiring specific documentation. While several countries in the region, including Australia and New Zealand, accept English-language study documentation, other APAC markets may require some level of localization. In Malaysia and India, protocols and regulatory submissions are often accepted in English, but patient-facing materials and informed consent documents require translation into local languages, whereas many East Asian nations require translation of all documentation.

What should sponsors consider before expanding into APAC?

Early strategic planning is essential for sponsors considering expansion into APAC. The diversity of regulatory systems, patient populations, and operational environments means that successful trials begin with asking the right set of key questions early in the planning process.

Initially, it is key to determine which countries best align with the phase and therapeutic indication of the trial, as different markets across the region offer distinct advantages depending on the study’s objectives. Early-phase trials benefit from nations with streamlined application processes and specialized infrastructure, whereas later-phase trials often depend on access to large patient populations and established networks of sites.

Second, sponsors must consider which timelines truly matter within their development program. In some cases, rapid study start-up may be the primary priority, whereas in others, the focus may be on recruitment scale or the ability to generate data to support global regulatory submissions. Understanding these priorities early helps to determine which APAC markets can best support the overall development strategy.

Finally, identifying where local expertise and on-the-ground support are needed is essential before a trial begins. Navigating the complexity of multiple regulatory systems, cultural environments, and clinical networks makes local insight critical to planning studies realistically and executing them efficiently.

Making APAC work through an informed strategy

The diversity of the APAC region is often what makes it appear complex to sponsors entering the market for the first time. In reality, this diversity is one of its greatest strengths. The region offers a wide range of capabilities to support clinical trials throughout the development lifecycle.

Sponsors need to work with partners who understand regional nuances and global clinical trial processes. Organizations with experience across the APAC region can help sponsors to navigate country-specific requirements, support local engagement, and anticipate challenges before they impact timelines.

By combining global clinical trial expertise with regional insights, CROs such as Indero can support sponsors in designing and executing trials that fully leverage the opportunities available across the region. When working with a valued partner, and when integrated into development planning from the start, the region serves as a strategic component of global trial design.

About the author

Siow Bee Seu is director of clinical operations for APAC at Indero, a specialized, dual-focus CRO for dermatology and rheumatology clinical trials.